Jazz Pharmaceuticals plc (J7Z) - Total Assets
Based on the latest financial reports, Jazz Pharmaceuticals plc (J7Z) holds total assets worth €11.86 Billion EUR (≈ $13.87 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Jazz Pharmaceuticals plc - Total Assets Trend (2013–2025)
This chart illustrates how Jazz Pharmaceuticals plc's total assets have evolved over time, based on quarterly financial data. Also see Jazz Pharmaceuticals plc market cap and net worth for the company's overall valuation and market capitalisation.
Jazz Pharmaceuticals plc - Asset Composition Analysis
Current Asset Composition (December 2025)
Jazz Pharmaceuticals plc's total assets of €11.86 Billion consist of 35.7% current assets and 64.3% non-current assets. Review how much debt does Jazz Pharmaceuticals plc carry to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 11.9% |
| Accounts Receivable | €830.75 Million | 7.1% |
| Inventory | €416.96 Million | 3.6% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €4.43 Billion | 38.0% |
| Goodwill | €1.83 Billion | 15.7% |
Asset Composition Trend (2013–2025)
This chart illustrates how Jazz Pharmaceuticals plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Jazz Pharmaceuticals plc share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jazz Pharmaceuticals plc's current assets represent 35.7% of total assets in 2025, a decrease from 38.6% in 2013.
- Cash Position: Cash and equivalents constituted 11.9% of total assets in 2025, down from 28.4% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 52.0% of total assets, a decrease from 56.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 38.0% of total assets.
Jazz Pharmaceuticals plc Competitors by Total Assets
Key competitors of Jazz Pharmaceuticals plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Jazz Pharmaceuticals plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.04 | 3.38 | 3.35 |
| Quick Ratio | 1.85 | 2.97 | 1.93 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €2.34 Billion | €2.91 Billion | €2.07 Billion |
Jazz Pharmaceuticals plc - Advanced Valuation Insights
This section examines the relationship between Jazz Pharmaceuticals plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.11 |
| Latest Market Cap to Assets Ratio | 1.02 |
| Asset Growth Rate (YoY) | -2.9% |
| Total Assets | €11.66 Billion |
| Market Capitalization | $11.86 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Jazz Pharmaceuticals plc's assets above their book value (1.02x), reflecting positive investor sentiment about the company's future prospects.
Slight Asset Contraction: Jazz Pharmaceuticals plc's assets decreased by 2.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Jazz Pharmaceuticals plc (2013–2025)
The table below shows the annual total assets of Jazz Pharmaceuticals plc from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €11.66 Billion ≈ $13.63 Billion |
-2.94% |
| 2024-12-31 | €12.01 Billion ≈ $14.04 Billion |
+5.43% |
| 2023-12-31 | €11.39 Billion ≈ $13.32 Billion |
+5.15% |
| 2022-12-31 | €10.84 Billion ≈ $12.67 Billion |
-11.90% |
| 2021-12-31 | €12.30 Billion ≈ $14.38 Billion |
+88.17% |
| 2020-12-31 | €6.54 Billion ≈ $7.64 Billion |
+18.00% |
| 2019-12-31 | €5.54 Billion ≈ $6.48 Billion |
+6.45% |
| 2018-12-31 | €5.20 Billion ≈ $6.08 Billion |
+1.56% |
| 2017-12-31 | €5.12 Billion ≈ $5.99 Billion |
+6.74% |
| 2016-12-31 | €4.80 Billion ≈ $5.61 Billion |
+44.04% |
| 2015-12-31 | €3.33 Billion ≈ $3.90 Billion |
-0.19% |
| 2014-12-31 | €3.34 Billion ≈ $3.90 Billion |
+49.18% |
| 2013-12-31 | €2.24 Billion ≈ $2.62 Billion |
-- |
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC)… Read more